Logo

BMS' Deucravacitinib (BMS-986165) Demonstrate Superiority Over Amgen' Otezla (apremilast) in P-III POETYK PSO-1 Study for Plaque Psoriasis

Share this

BMS' Deucravacitinib (BMS-986165) Demonstrate Superiority Over Amgen' Otezla (apremilast) in P-III POETYK PSO-1 Study for Plaque Psoriasis

Shots:

  • The P-III POETYK PSO-1 study involves assessing deucravacitinib (6mg- qd) vs PBO & Otezla (apremilast) in 666 patients with moderate to severe plaque psoriasis
  • The trial met its co-1EPs & 2EPs demonstrating deucravacitinib was superior to Otezla (apremilast) in the patients reaching a PASI 75 and sPGA 0/1 @16wks. The overall safety profile of deucravacitinib was consistent with previously reported P-II results
  • Deucravacitinib (BMS-986165- PO) is the first & only novel selective TYK2 inhibitor- currently being evaluated in psoriasis- PsA- lupus- and IBD

  Ref: Businesswire | Image: BMS

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions